Page last updated: 2024-11-06

prednisolone and Hemangioma, Capillary

prednisolone has been researched along with Hemangioma, Capillary in 14 studies

Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.

Hemangioma, Capillary: A dull red, firm, dome-shaped hemangioma, sharply demarcated from surrounding skin, usually located on the head and neck, which grows rapidly and generally undergoes regression and involution without scarring. It is caused by proliferation of immature capillary vessels in active stroma, and is usually present at birth or occurs within the first two or three months of life. (Dorland, 27th ed)

Research Excerpts

Excerpt	Relevance	Reference
"Infantile hemangiomas are the most common benign vascular tumors in childhood."	5.56	Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020)
"Infantile hemangiomas are the most common benign vascular tumors in childhood."	1.56	Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020)

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (7.14)	18.2507
2000's	5 (35.71)	29.6817
2010's	7 (50.00)	24.3611
2020's	1 (7.14)	2.80

Authors

Authors	Studies
Dávila-Osorio, VL	1
Iznardo, H	1
Roé, E	1
Puig, L	1
Baselga, E	2
Novoa, M	1
Beltran, S	1
Giraldo, L	1
Shahbaz, A	1
Pardo-Hernandez, H	1
Arevalo-Rodriguez, I	1
Mendoza-Cruz, AC	1
Wargon, O	1
Adams, S	1
Tran, H	1
Verge, CF	1
Léauté-Labrèze, C	1
Dumas de la Roque, E	1
Hubiche, T	1
Boralevi, F	1
Thambo, JB	1
Taïeb, A	1
Wasong, SJ	1
Klepeiss, SA	1
Zaenglein, AL	1
Tamai, N	1
Hashii, Y	1
Osuga, K	1
Chihara, T	1
Morii, E	1
Aozasa, K	1
Yoshikawa, H	1
Fulkerson, DH	1
Agim, NG	1
Al-Shamy, G	1
Metry, DW	1
Izaddoost, SA	1
Jea, A	1
Grover, C	1
Arora, P	1
Kedar, A	1
Pal, P	1
Lal, B	1
Koay, AC	1
Choo, MM	1
Nathan, AM	1
Omar, A	1
Lim, CT	1
Leonardi-Bee, J	1
Batta, K	1
O'Brien, C	1
Bath-Hextall, FJ	1
Kiratli, H	1
Bilgiç, S	1
Cağlar, M	1
Söylemezoğlu, F	1
Ioannidis, AS	1
Liasis, A	1
Syed, S	1
Harper, J	1
Nischal, KK	1
Spalding, SJ	1
Hennon, T	1
Dohar, J	1
Arkachaisri, T	1
Nanda, VS	1

Clinical Trials (10)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study[NCT02012777]	Phase 1	9 participants (Actual)	Interventional	2010-06-30	Terminated (stopped due to Inability to recruit patients into the study.)
A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double[NCT01056341]	Phase 2/Phase 3	512 participants (Actual)	Interventional	2010-01-31	Completed
Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study[NCT00967226]	Phase 2	19 participants (Actual)	Interventional	2009-07-31	Terminated (stopped due to Serious adverse events with prednisolone, primarily temporary growth retardation, <5th percentile.)
Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence[NCT02962947]	Phase 2/Phase 3	546 participants (Anticipated)	Interventional	2017-06-30	Not yet recruiting
"'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma"[NCT04684667]	Phase 2	100 participants (Anticipated)	Interventional	2021-01-01	Not yet recruiting
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242]	Phase 2	22 participants (Actual)	Interventional	2015-05-23	Completed
A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma[NCT01072045]	Phase 2	50 participants (Actual)	Interventional	2010-01-31	Completed
A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)[NCT05983159]	Phase 2	30 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Double Blind, Randomised, Placebo-controlled Study of Propranolol in Infantile Capillary Hemangiomas[NCT00744185]	Phase 2/Phase 3	14 participants (Actual)	Interventional	2008-10-31	Terminated (stopped due to Study halted prematurely due to some difficulties in recruitment of patients)
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol[NCT01533376]	Phase 1	3 participants (Actual)	Interventional	2012-02-29	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of Week 24 Photographs.

(NCT01056341)
Timeframe: 6 months

Intervention	percentage of participants (Number)
Placebo	8.0
Propranolol 1mg/kg/d 3 Months	9.8
Propranolol 1 mg/kg/d 6 Months	37.5
Propranolol 3 mg/kg/d 3 Months	7.7
Propranolol 3 mg/kg/d 6 Months	62.8

Primary Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at W24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of W24 Photographs.

(NCT01056341)
Timeframe: 6 months

Intervention	percentage of participants (Number)
Placebo	3.6
Propranolol 3mg/kg/d 6 Months	60.4

Allergy/Immunology Adverse Events

Number of allergy/immunology AE per study arm (NCT00967226)
Timeframe: enrollment through study closeout or study withdrawal up to 9 months

Intervention	Adverse Events (Number)
Allergy/Immunology Events Propranolol	1
Allergy/Immunology Events Prednisolone	1

Constitutional Adverse Events

Number of constitutional AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months

Intervention	Adverse Events (Number)
Constitutional AEs Propranolol	2
Constitutional AEs Prednisolone	3

Decrease in Size of Hemangioma (Length x Width) in Square mm

A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available. (NCT00967226)
Timeframe: 4-5 months after initiating therapy

Intervention	mm squared (Mean)
Propranolol	0.57
Prednisolone	0.63

Dermatologic Adverse Events

Number of Dermatologic Adverse Events in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months

Intervention	Adverse Events (Number)
Dermatologic AEs Propranolol	2
Dermatologic AEs Prednisolone	1

Endocrinologic Adverse Events

Number of Endocrinologic AEs (of which adrenal crisis does not overlap). (NCT00967226)
Timeframe: enrollment to close out or study withdrawal up to 9 months

Intervention	Adverse Events (Number)
Endocrine AEs Propranolol	0
Endocrinologic AEs Prednisolone	7

Gastrointestinal Adverse Events

Number of Gastrointestinal AEs in each arm (NCT00967226)
Timeframe: enrollment to study withdrawal or study close out up to 9 months

Intervention	Adverse Events (Number)
Gastrointestinal AEs Propranolol	6
Gastrointestinal AEs Prednisolone	6

Growth and Development Adverse Events

Number of Growth and Development AEs in each study arm (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

Intervention	Adverse Events (Number)
Growth/Developoment AEs Propranolol	0
Growth/Development AEs Prednisolone	1

Infectious Adverse Events

Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever) (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

Intervention	Adverse Events (Number)
Infectious AEs Propranolol	5
Infectious AEs Prednisolone	3

Metabolic or Laboratory AEs

Number of Metabolic or Laboratory AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

Intervention	Adverse Events (Number)
Metabolic/Laboratory AEs Propranolol	1
Metabolic/Laboratory AEs Prednisolone	0

Number of Serious Adverse Events (SAEs)

Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months

Intervention	Serious Adverse Events (Number)
Number of Serious Adverse Events in Propranolol	1
Number of Serious Adverse Events in Prednisolone	11

Pulmonary/Respiratory Adverse Events

Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm (NCT00967226)
Timeframe: enrollment through study close out or withdrawal, up to 9 months

Intervention	Adverse Events (Number)
Pulmonary/Respiratory AEs Propranolol	14
Pulmonary/Respiratory AEs Prednisolone	4

Vascular Adverse Events

Number of Vascular AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

Intervention	Adverse Events (Number)
Vascular AEs Propranolol	3
Vascular AEs Prednisolone	4

Tolerability of Medication

All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months

Intervention	Events (Number)
	Adverse Events	Serious Adverse Events
Overall Number of Adverse Events in Prednisolone	30	11
Overall Number of Adverse Events in Propranolol	34	1

Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination.

Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20

Intervention	percentage of volume (Mean)
Double-Blind Placebo	5.89
Open-Label Sildenafil	-8.54
Double-blind Sildenafil	-0.642

Change in Subject's Assessment of Change in Lymphatic Malformation Overall Score

"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20

Intervention	Participants (Count of Participants)
	No improvement	Minimal improvement	Fair improvement	Good improvement	Excellent improvement
Double-Blind Placebo	1	2	0	2	0
Double-Blind Sildenafil	2	4	1	1	0

Reviews

3 reviews available for prednisolone and Hemangioma, Capillary

Article	Year
Interventions for infantile haemangiomas of the skin. The Cochrane database of systematic reviews, 2018, 04-18, Volume: 4 Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Antineoplastic Agents; Bleomycin; Child, Presc	2018
Emergent medical and surgical management of mediastinal infantile hemangioma with symptomatic spinal cord compression: case report and literature review. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2010, Volume: 26, Issue:12 Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Anticoagulants; Child, Preschool; Decompressi	2010
Interventions for infantile haemangiomas (strawberry birthmarks) of the skin. The Cochrane database of systematic reviews, 2011, May-11, Issue:5 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Bleomycin; Child, Preschool; Hemangioma, Capillary;	2011

Other Studies

11 other studies available for prednisolone and Hemangioma, Capillary

Article	Year
Propranolol-resistant infantile hemangioma successfully treated with sirolimus. Pediatric dermatology, 2020, Volume: 37, Issue:4 Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Hemangioma, Capillary; Humans; Infant; Prednisolone;	2020
Hypothalamic-pituitary-adrenal axis recovery following prolonged prednisolone therapy in infants. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:12 Topics: Antineoplastic Agents, Hormonal; Child Development; Circadian Rhythm; Female; Follow-Up Studies; Glu	2013
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Picture of the month. Ulcerated infantile hemangioma. Archives of pediatrics & adolescent medicine, 2008, Volume: 162, Issue:9 Topics: Diagnosis, Differential; Drug Therapy, Combination; Gentamicins; Hemangioma, Capillary; Humans; Infa	2008
Kaposiform hemangioendothelioma arising in the deltoid muscle without the Kasabach-Merritt phenomenon. Skeletal radiology, 2010, Volume: 39, Issue:10 Topics: Antineoplastic Agents, Hormonal; Deltoid Muscle; Diagnosis, Differential; Disseminated Intravascular	2010
Combination of oral corticosteroids and polidocanol sclerotherapy in the management of infantile hemangiomas. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2010, Volume: 36, Issue:12 Topics: Administration, Oral; Adrenal Cortex Hormones; Combined Modality Therapy; Female; Hemangioma, Capill	2010
Combined low-dose oral propranolol and oral prednisolone as first-line treatment in periocular infantile hemangiomas. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2011, Volume: 27, Issue:3 Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Therapy, Combination; Eyelid Diseases; Femal	2011
Intramuscular hemangiomas of extraocular muscles. Ophthalmology, 2003, Volume: 110, Issue:3 Topics: Administration, Oral; Adult; Child, Preschool; Glucocorticoids; Hemangioma, Capillary; Humans; Magne	2003
The value of visual evoked potentials in the evaluation of periorbital hemangiomas. American journal of ophthalmology, 2005, Volume: 140, Issue:2 Topics: Amblyopia; Astigmatism; Evoked Potentials, Visual; Eyelid Neoplasms; Facial Neoplasms; Female; Gluco	2005
Neonatal lupus erythematosus complicated by mucocutaneous and visceral hemangiomas. Lupus, 2007, Volume: 16, Issue:11 Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Female; Hemangioma, Capillary; Humans; Inf	2007
Management of capillary hemangiomas. The Western journal of medicine, 1994, Volume: 160, Issue:4 Topics: Administration, Oral; Eyelid Neoplasms; Hemangioma, Capillary; Humans; Interferon alpha-2; Interfero	1994